Why the “Critical Window” May Not Be Closed After All
Hormone replacement therapy (HRT) has long been a fraught topic in women’s health, especially for those navigating menopause and beyond. For years, the message was clear: if you missed your “window”—usually defined as within 10 years of menopause or before age 60—HRT was considered too risky to start. But what about the vibrant, proactive woman in her late 60s or early 70s who’s metabolically healthy and seeking solutions for fragmented sleep, bone loss, or dementia risk? Is it truly too late for her? Recent insights, reviewed by Dr. Betty Murray on the Menopause Mastery Podcast, suggest that the answer is far more nuanced and that the evidence is evolving.
Let’s dive into the myths, gaps, and emerging research on HRT for women 65 and older.
The HRT “No Man’s Land”: How We Got Here
The roots of the “too late for HRT” refrain trace back to the 2002 Women’s Health Initiative (WHI), a landmark study that dramatically changed clinical guidelines overnight. WHI participants—many of whom were already older, with high rates of obesity, hypertension, and other risks—were given oral conjugated equine estrogens and synthetic progestins. The results implicated HRT in an increased rate of stroke, clotting, and cardiovascular events, leading the medical community to largely abandon HRT for older women.
But as Dr. Betty Murray explained, the fallout created a research vacuum—one that left millions of women in a “no man’s land,” without evidence-based answers specific to their age group, health status, or personal risk factors. Most studies were never designed to address nuanced questions about delivery method, bioidentical hormones, or the realities of today’s longer postmenopausal lifespan.
Debunking the Myth: Is HRT Always Dangerous After 65?
For the majority of providers, the answer to “Can I start HRT after 65?” remains a reflexive, population-based “No.” But the presence of new, healthy, and metabolically robust older women challenges this one-size-fits-all answer.
Dr. Betty Murray emphasized that key factors must be considered: delivery method (oral vs. transdermal), an individual’s genetics (like APOE4 Alzheimer’s risk), and comorbidities. Transdermal (patch, cream, or gel) estrogen is fundamentally different from the oral forms tested in the WHI. Oral estrogens pass through the liver, creating metabolites that heighten clotting risk—especially dangerous in older women. Transdermal estrogen, on the other hand, largely bypasses this first-pass effect, dramatically lowering the risk for clotting, stroke, and heart attack.
Observational studies—even enormous Medicare datasets following millions of women—show that transdermal HRT does not increase risk of deep vein thrombosis, stroke, or heart attacks in older women. While some clinicians argue only randomized, controlled trials provide “real” evidence, Dr. Betty Murray points out that much of what modern medicine prescribes is based on well-conducted observational or retrospective research. We don’t assign people to smoke or not for 30 years to prove cigarettes cause cancer—it’s unethical and unnecessary.
Bone Health: A Clinically Proven Benefit of HRT—at Any Age
One of the most robustly researched benefits of HRT, even for those who start later in life, is the preservation of bone health. Osteoporosis and the resulting fractures are a silent yet deadly threat to women after 65; half of women who break a major bone will not survive their first year afterward, and most lose mobility and independence.
Data shows that continuous transdermal estrogen reduces all clinical fractures by 27% in postmenopausal women—even those well past the typical “window.” The benefit is both in maintaining and, in some cases, rebuilding bone density, provided therapy is continued. Once stopped, the protective effects dissipate after about five years. In Dr. Betty Murray’s own clinical practice, even women already on bone drugs for osteoporosis get additional benefit from transdermal estrogen—which does not magically halt at age 60 or 65.
Sleep, Cognition, and Dementia: Why HRT Deserves a Second Look
Quality sleep is a modifiable risk factor for cognitive decline and dementia—a growing concern as our lifespan stretches. Insomnia and sleep fragmentation in postmenopausal women increase dementia risk by up to 36%. Estrogen, particularly when delivered transdermally, appears to improve overall sleep quality, enhancing deep and REM sleep. These improvements, while often overlooked, could translate into meaningful protection against Alzheimer’s and other dementias, especially for APOE4 gene carriers.
While the evidence is still developing, Dr. Betty Murray notes that, especially for symptomatic women—those experiencing anxiety, depression, poor sleep, or concern about cognitive decline—these potential benefits deserve serious consideration in a shared, informed decision-making process.
Cardiovascular Risk: Navigating the Evidence
The area of greatest caution remains women with known cardiovascular disease or unmanaged risk factors. Oral estrogen—especially started more than ten years after menopause—can “remodel” arterial plaques, potentially increasing the risk of heart attack or stroke if significant disease is present.
However, careful individualized risk assessment (through advanced screening like coronary calcium scores, CIMT, or CT angiograms) can help many women without established vascular disease safely consider HRT. The takeaway? Proper screening and conservative, low-dose transdermal approaches can mitigate much of the historic risk, particularly in healthy, non-smoking, metabolically stable women.
Making a Personalized Decision: The Path Forward
Women in their late 60s or 70s considering HRT should be guided by a clinician willing to go beyond outdated guidelines and explore actual personal risk. Dr. Betty Murray recommends a thorough review of bone density, sleep quality, cognitive symptoms, and heart health—using not just age, but health status and patient preference as guiding factors.
It’s crucial to understand and accept that we don’t have all the answers—because the studies simply don’t exist. In many ways, today’s generation of women over 65 are pioneers, refusing the “inevitability” of brittle bones or dementia and demanding data-driven, individualized care.
Vaginal Estrogen: A Universal Must
Regardless of age, nearly every woman can benefit from vaginal estrogen. Continuous use lowers UTI risk by 86%, a key cause of fatal sepsis in older women. Protecting genitourinary health is about more than comfort—it’s a matter of long-term wellbeing and independence.
The Bottom Line: Is It Too Late?
If you’re a woman in your late 60s, 70s, or beyond, in generally good health, and facing quality-of-life concerns like osteoporosis, insomnia, or cognitive worry, HRT—especially transdermal, with proper medical partnership—is not automatically off the table. The “age cutoff” is an outdated myth, not supported by the totality of emerging evidence.
Shared decision-making, grounded in your unique health profile and values, should be the rule—not the exception—as we close the evidence gap left by decades of underfunding and fear-driven guidelines.
You deserve choices, and it’s never too late to take the next step toward your best possible health.
You can watch the complete episode here: Is It Too Late for Hormone Replacement Therapy?
For more in-depth discussions and the latest on menopause care, subscribe to the Menopause Mastery Podcast with Dr. Betty Murray — and join the growing movement toward evidence-based, empowered aging.
Other Links to check out:
